Back to search

United Kingdom· GB-APID-29980211000001109

Brilique 90mg tablets

A ticagrelor product containing ticagrelor, registered in United Kingdom by Lexon (UK) Ltd. The same ATC class is registered in 18 of our 19 countries.

ATC B01AC24

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedBrilique 90mg tabletsATCB01AC24REGISTER NO.GB-APID-2998021100000…PACKS LISTED0CHECKEDSeptember 13, 2026

Where it is registered

Ticagrelor is registered in 18 of 19 countries.

Countries holding a registration under ATC B01AC24 (ticagrelor), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 10 of them publish a price we can compare per daily dose

Ticagrelor · ATC B01AC24

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ticagrelor costs, country by country.

Normalised to the WHO defined daily dose (0.18 g), the median price runs from $0.68 in United States to $1.97 in Spain — a ×2.9 gap.

  • 5 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Ticagrelor · price per daily dose (0.18 g)

USD · FX 28 Sept 2026

  • ES Spain$1.97
  • CH Switzerland$1.80
  • IT Italy$0.94
  • FR France$0.77
  • US United States$0.68 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Ticagrelor
Manufacturer
Lexon (UK) Ltd
Country
United Kingdom (GB)
ATC code
B01AC24
ATC class
Ticagrelor
Defined daily dose
0.18 g, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

529 interactions on record for ticagrelor.

Graded by severity as the source publishes them — 76 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ticagrelor · interactions on record

529 records

  • 76 severe
  • 354 moderate
  • 60 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • DanaparoidB01AB09severe

39 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ticagrelor in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ticagrelor products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Ticagrelor, Ticagrelor Accord
  • Belgium · Ticagrelor Ab, Ticagrelor Eg
  • Bulgaria · ?????????? Accord, Tilobrastil
  • Cyprus · Brirem, Lacrat
  • Czechia · Atirabo, Atixarso
  • Germany · Ticabril, Ticagrelor
  • Denmark · Lacrat, Ticagrelor Accord
  • Estonia · Agtileq, Atirabo
  • Spain · Lacrat, Ticagrelor Abdi
  • Finland · Ticagrelor Accord, Ticagrelor Avansor
  • France · Ticagrelor Accord, Ticagrelor Arrow
  • Greece · Agilinta, Atixarso
  • Croatia · Atixarso, Greccas
  • Hungary · Atirabo, Atixarso
  • Ireland · Ticagrelor Accord, Ticagrelor Bluefish
  • Iceland · Brilique, Ticagrelor Krka
  • Italy · Auretica, Ticagrelor
  • Liechtenstein · Brilique
  • Lithuania · Atirabo, Atixarso
  • Luxembourg · Ticagelor Eg (Eurogenerics) Nv, Ticagrelor Eg
  • Latvia · Atirabo, Atixarso
  • Malta · Brirem, Croalcril
  • Netherlands · Ticagrelor Abdi, Ticagrelor Accord
  • Norway · Brilique, Ticagrelor Accord
  • Poland · Atirabo, Atixarso
  • Portugal · Brirem, Lacrat Mg
  • Romania · Atixarso, Croalcril
  • Sweden · Auretica, Ecugra
  • Slovenia · Atixarso, Lacrat
  • Slovakia · Atirabo, Atixarso

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b9a20aa7-157e-492c-bc1c-9ebc62c2423b
GET /v1/drugs/b9a20aa7-157e-492c-bc1c-9ebc62c2423b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "29980211000001109",
  "desc": "Brilique 90mg tablets (Lexon (UK) Ltd)",
  "form": "Oral tablet",
  "vpid": "42298811000001100",
  "source": "dmd",
  "vtm_id": "777766002",
  "strength": "90 mg",
  "substance": "Ticagrelor",
  "ingredient": "Ticagrelor",
  "supplier_code": "3415501000001104"
}

See everything about ticagrelor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.